Last week, TrialAssure took the proactive effort to create and publish nearly 50,000 AI-generated plain language summaries (PLSs) from clinical trial results posted directly to TrialResults.com. This includes plain language summaries for every clinical trial that has had results posted on the National Institutes of Health’s (NIH) ClinicalTrials.gov website since 2020.
Releasing the AI-generated plain language summary documents in phases, the grouping of metabolic disorder documents are now available. This includes the following indications:
- Type 1 Diabetes
- Type 2 Diabetes Mellitus
- Obesity
- Hypercholesterolemia
- Other metabolic disorders
Harnessing the power of generative artificial intelligence (AI), proprietary TrialAssure LINK® software has been used to translate the clinical trial results data—sourced from ClinicalTrials.gov—into user-friendly plain language summaries.
Aimed at simplifying complex clinical trial results, these summaries are diligently crafted to match a 6th-8th grade reading level. Their growing popularity, even in a U.S. market where they remain voluntary, echoes the mounting demand for pharmaceutical transparency.
Individuals and organizations interested in delving into specific clinical trials, especially those related to metabolic disorders, can search all summaries on TrialResults.com.
Simply inputting a disease name, condition, or study identifier allows users to access a comprehensive plain language summary from the extensive archive. Every summary credits its study sponsor, directing users to more in-depth information on the corresponding websites.
Visit TrialResults.com to access these documents now or contact us with any questions and a demo of our TrialAssure LINK tool.
If you’re a Sponsor and have your own PLS currently written, please email us at connect@trialassure.com and we will link directly to it.
